Sickle Cell Disease Treatment Market by Indication and Geography - Forecast and Analysis 2021-2025

Published: Jan 2022 Pages: 120 SKU: IRTNTR72069

The sickle cell disease treatment market share is expected to increase to USD 2.33 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 11.36%.

This sickle cell disease treatment market research report extensively covers market segmentation by indication (sickle cell anemia and others) and geography (North America, Europe, Asia, and ROW).

The sickle cell disease treatment market report also offers information on several market vendors, including Addmedica SAS, Bristol-Myers Squibb Co., Chiesi Pharmaceuticals BV, CRISPR Therapeutics AG, Emmaus Life Sciences Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Medunik USA, Novartis AG, and Pfizer Inc. among others. Furthermore, this report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches.

What will the Sickle Cell Disease Treatment Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Sickle Cell Disease Treatment Market Size for the Forecast Period and Other Important Statistics

 

Sickle Cell Disease Treatment Market: Key Drivers, Trends, and Challenges

The high prevalence of sickle cell disease is notably driving the sickle cell disease treatment market growth, although factors such as the high cost of treatment may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the sickle cell disease treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Sickle Cell Disease Treatment Market Driver

The high prevalence of sickle cell disease is one of the key drivers supporting the sickle cell disease treatment market growth. The global sickle cell disease treatment market has witnessed a significant increase in the number of cases of sickle cell diseases in recent years. For instance, in the US, the estimated average yearly emergency department visits and hospitalizations by patients with sickle cell disease is around 200,000 and over 100,000, respectively. However, the disease is more common in African-Americans, with the prevalence being as high as one per every 365 people. Currently, around 300,000 affected babies are born each year where more than 80% is accounted for by Africa. Thus, this increasing number of sickle cell diseases may drive market growth during the forecast period.

Key Sickle Cell Disease Treatment Market Trend

The strong pipeline is another factor supporting the sickle cell disease treatment market growth. The pipeline for sickle cell disease comprises strong pharmaceutical companies with novel therapies in the clinical trials and various mid and small pharmaceutical companies with early-stage pipeline drugs. The strong efficacy of these drugs in the early stages of clinical trials has led to a positive opinion from the regulatory bodies, thus helping the vendors with the quick development of these drugs. Recent advances in technology and the diagnosis of sickle cell are also driving factors behind the strong pipeline for the treatment of sickle cell diseases.

Key Sickle Cell Disease Treatment Market Challenge

The high cost of treatment is hindering the sickle cell disease treatment market growth. The recent launch of drugs such as Siklos, Endari, and DROXIA has seen the market accept therapeutic solutions but are too costly. Meanwhile, the curative nature of blood transfusion makes this the most preferred treatment option. However, this costly treatment option gets an additional cost factor in the form of hospital stay, which is mandatory for such procedures. As most of the countries do not have reimbursement plans or patient assistance programs, a large share of patients faces a challenge with the high costs of the drugs. The gene therapy programs that are being developed are also expected to be priced high, and the market is expected to face this challenge during the forecast period.

This sickle cell disease treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

Technavio categorizes the sickle cell disease treatment market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the sickle cell disease treatment market during the forecast period.

Who are the Major Sickle Cell Disease Treatment Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

  • Addmedica SAS
  • Bristol-Myers Squibb Co.
  • Chiesi Pharmaceuticals BV
  • CRISPR Therapeutics AG
  • Emmaus Life Sciences Inc.
  • Global Blood Therapeutics Inc.
  • GlycoMimetics Inc.
  • Medunik USA
  • Novartis AG
  • Pfizer Inc.

 

This statistical study of the sickle cell disease treatment market encompasses successful business strategies deployed by the key vendors. The sickle cell disease treatment market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

  • Addmedica SAS - The company offers sickle cell disease treatment such as Siklos Hydroxycarbamide.
  • Addmedica SAS - Under the unified segment, the company offers development and marketing of medical products for rare diseases, serious conditions and unmet medical needs.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The sickle cell disease treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Sickle Cell Disease Treatment Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the sickle cell disease treatment market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the pharmaceuticals market includes the following core components:

  • Research and development (R&D) and drug discovery
  • Integration and product development
  •  Manufacturing
  • Outbound logistics
  • Support services
  • Innovation

The report has further elucidated on other innovative approaches being followed by service providers to ensure a sustainable market presence.

 

Which are the Key Regions for Sickle Cell Disease Treatment Market?

For more insights on the market share of various regions Request for a FREE sample now!

40% of the market's growth will originate from North America during the forecast period. The US is the key market for the sickle cell disease treatment market in North America. Market growth in this region will be slower than the growth of the market in Asia.

The sales of approved therapeutics and the increasing cases of various types of sickle cell diseases will facilitate the sickle cell disease treatment market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the spread of COVID-19 across North America, especially in the US, reduced the demand for sickle cell disease treatment owing to the decrease in clinical presentations of patients to their general practitioners. As a result, the number of prescriptions for sickle cell disease treatment decreased in many North American countries such as the US, Canada, and Mexico and negatively impacted the market in focus in 2020. However, the market in the region is expected to recover gradually during the forecast period as telehealth has helped in safe access to and delivery of healthcare services which will help the market recover.

What are the Revenue-generating Indication Segments in the Sickle Cell Disease Treatment Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The sickle cell disease treatment market share growth by the sickle cell anemia segment will be significant during the forecast period. Sickle cell anemia is the most common type of sickle cell disease, with approximately two-thirds of cases falling under this category.  This segment is expected to witness significant growth during the forecast period, primarily due to the recent approvals and the expected launch of molecules

This report provides an accurate prediction of the contribution of all the segments to the growth of the sickle cell disease treatment market size and actionable market insights on post COVID-19 impact on each segment.

 

Sickle Cell Disease Treatment Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 11.36%

Market growth 2021-2025

$ 2.33 billion

Market structure

Fragmented

YoY growth (%)

10.83

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 40%

Key consumer countries

US, Germany, UK, China, and Japan

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Addmedica SAS, Bristol-Myers Squibb Co., Chiesi Pharmaceuticals BV, CRISPR Therapeutics AG, Emmaus Life Sciences Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Medunik USA, Novartis AG, and Pfizer Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Sickle Cell Disease Treatment Market Report?

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will drive sickle cell disease treatment market growth during the next five years
  • Precise estimation of the sickle cell disease treatment market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the sickle cell disease treatment industry across North America, Europe, Asia, and ROW
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of sickle cell disease treatment market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

***1. Executive Summary                           

                **1.1     Market Overview            

                                *Exhibit 01:  Key Finding 1

                                *Exhibit 02:  Key Finding 2

                                *Exhibit 03:  Key Finding 3

                                *Exhibit 04:  Key Finding 5

                                *Exhibit 05:  Key Finding 6

                                *Exhibit 06:  Key Finding 7

                                *Exhibit 07:  Key Finding 8

***2. Market Landscape             

             **2.1 Market ecosystem

                                *2.1.1 Parent Market

                                *Exhibit 08:  Parent market

                                *Exhibit 09:  Market characteristics

                **2.2 Value Chain Analysis          

                                *Exhibit 10:  Value Chain Analysis: Pharmaceuticals

                                *2.2.1    Research and development (R&D) and drug discovery

                                *2.2.2    Integration and product development

                                *2.2.3    Manufacturing

                                *2.2.4    Outbound logistics

                                *2.2.5    Marketing and sales

                                *2.2.6    Support services

                             *2.2.7   Innovation

***3. Market Sizing                       

                **3.1 Market definition

                                *Exhibit 11:  Offerings of vendors included in the market definition

                **3.2 Market segment analysis 

                                *Exhibit 12:  Market segments

                **3.3 Market size 2021 

                **3.4 Market outlook: Forecast for 2020 - 2025 

                                *3.4.1Estimating growth rates for emerging and high-growth markets

                                *3.4.2Estimating growth rates for mature markets

                                *Exhibit 13:  Global - Market size and forecast 2020 - 2025 ($ million)

                                *Exhibit 14:  Global market: Year-over-year growth 2020 - 2025 (%)

***4. Five Forces Analysis                          

                **4.1 Five Forces Summary        

                                *Exhibit 15:  Five forces analysis 2020 & 2025

                **4.2 Bargaining power of buyers           

                                *Exhibit 16: Bargaining power of the buyer

                **4.3 Bargaining power of suppliers       

                                *Exhibit 17: Bargaining power of the supplier

                **4.4 Threat of new entrants    

                                *Exhibit 18: Threat of new entrants

                **4.5 Threat of substitutes         

                                *Exhibit 19: Threat of substitutes

                **4.6 Threat of rivalry   

                                *Exhibit 20: Threat of rivalry

                **4.7 Market condition

                                *Exhibit 21: Market condition - Five forces 2020

***5. Market Segmentation by Indication          

              **5.1 Market segments

                                *Exhibit 22:  Indication- Market share 2020-2025 (%)

                **5.2 Comparison by Indication

                                *Exhibit 23:  Comparison by Indication

                **5.3 Sickle cell anemia - Market size and forecast 2020-2025      

                                *Exhibit 24:  Sickle cell anemia - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 25:  Sickle cell anemia - Year-over-year growth 2020-2025 (%)

                **5.4 Sickle beta thalassemia  - Market size and forecast 2020-2025         

                                *Exhibit 26:  Sickle beta thalassemia  - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 27:  Sickle beta thalassemia  - Year-over-year growth 2020-2025 (%)

                **5.5 Others - Market size and forecast 2020-2025           

                                *Exhibit 28:  Others - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 29:  Others - Year-over-year growth 2020-2025 (%)

                **5.6 Market opportunity by Indication

                                *Exhibit 30:  Market opportunity by Indication

***6. Customer landscape                         

                                *Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria

                **6.1 Overview

                                *Exhibit 31:  Customer landscape

***7. Geographic Landscape                     

                **7.1 Geographic segmentation

                                *Exhibit 32:  Market share by geography 2020-2025 (%)

                **7.2 Geographic comparison   

                                *Exhibit 33:  Geographic comparison

                **7.3 North America - Market size and forecast 2020-2025           

                                *Exhibit 34:  North America - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 35:  North America - Year-over-year growth 2020-2025 (%)

                **7.4 Europe - Market size and forecast 2020-2025          

                                *Exhibit 36:  Europe - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 37:  Europe - Year-over-year growth 2020-2025 (%)

                **7.5 Asia - Market size and forecast 2020-2025

                                *Exhibit 38:  Asia - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 39:  Asia - Year-over-year growth 2020-2025 (%)

                **7.6 ROW- Market size and forecast 2020-2025               

                                *Exhibit 40:  ROW - Market size and forecast 2020-2025 ($ million)

                                *Exhibit 41:  ROW - Year-over-year growth 2020-2025 (%)

                **7.7 Key leading countries        

                                *Exhibit 42:  Key leading countries

                **7.8 Market opportunity by geography

                                *Exhibit 43:  Market opportunity by geography ($ million)

***8. Drivers, Challenges, and Trends                   

                **8.1 Market drivers     

                                *8.1.1    High prevalence of sickle cell disease

                                *8.1.2    Provision of special drug designations

                                *8.1.3    Increase in screening tests on infants

                **8.2 Market challenges              

                                *8.2.1    High cost of treatment

                                *8.2.2    Lack of approved therapies

                                *8.2.3    Stringent regulatory policies

                                *Exhibit 44:  Impact of drivers and challenges

                **8.3 Market trends      

                                *8.3.1    Strong pipeline

                                *8.3.2    Advent of regenerative therapy

                                *8.3.3    New treatments

***9. Vendor Landscape                             

                **9.1 Overview

                                *Exhibit 45:  Vendor landscape

                **9.2 Landscape disruption        

                                *Exhibit 46:  Landscape disruption

                                *Exhibit 47: Industry Risk

                **9.3 Competitive Scenario        

***10. Vendor Analysis               

                **10.1 Vendors covered              

                                *Exhibit 48: Vendors covered

                **10.2 Market positioning of vendors    

                                *Exhibit 49: ?Market positioning of vendors?

                **10.3 Addmedica SAS 

                                *Exhibit 50:  Addmedica SAS - Overview

                                *Exhibit 51:  Addmedica SAS - Product and service

                                *Exhibit 52:  Addmedica SAS - Key offerings

                **10.4 Bristol-Myers Squibb Co.

                                *Exhibit 53:  Bristol-Myers Squibb Co. - Overview

                                *Exhibit 54:  Bristol-Myers Squibb Co. - Product and service

                                *Exhibit 55:  Bristol-Myers Squibb Co. - Key offerings

                **10.5 Chiesi Pharmaceuticals BV            

                                *Exhibit 56:  Chiesi Pharmaceuticals BV - Overview

                                *Exhibit 57:  Chiesi Pharmaceuticals BV - Product and service

                                *Exhibit 58:  Chiesi Pharmaceuticals BV - Key offerings

                **10.6 CRISPR Therapeutics AG

                                *Exhibit 59:  CRISPR Therapeutics AG - Overview

                                *Exhibit 60:  CRISPR Therapeutics AG - Business segments

                                *Exhibit 61:  CRISPR Therapeutics AG - Key offerings

                                *Exhibit 62:  CRISPR Therapeutics AG - Segment focus

                **10.7 Emmaus Life Sciences Inc.             

                                *Exhibit 63:  Emmaus Life Sciences Inc. - Overview

                                *Exhibit 64:  Emmaus Life Sciences Inc. - Business segments

                                *Exhibit 65:  Emmaus Life Sciences Inc. - Key offerings

                                *Exhibit 66:  Emmaus Life Sciences Inc. - Segment focus

                **10.8 Global Blood Therapeutics Inc.   

                                *Exhibit 67:  Global Blood Therapeutics Inc. - Overview

                                *Exhibit 68:  Global Blood Therapeutics Inc. - Business segments

                                *Exhibit 69:  Global Blood Therapeutics Inc. - Key offerings

                                *Exhibit 70:  Global Blood Therapeutics Inc. - Segment focus

                **10.9 GlycoMimetics Inc.          

                                *Exhibit 71:  GlycoMimetics Inc. - Overview

                                *Exhibit 72:  GlycoMimetics Inc. - Business segments

                                *Exhibit 73:  GlycoMimetics Inc. - Key offerings

                                *Exhibit 74:  GlycoMimetics Inc. - Segment focus

                **10.10 Medunik USA  

                                *Exhibit 75:  Medunik USA - Overview

                                *Exhibit 76:  Medunik USA - Product and service

                                *Exhibit 77:  Medunik USA - Key offerings

                **10.11 Novartis AG      

                                *Exhibit 78:  Novartis AG - Overview

                                *Exhibit 79:  Novartis AG - Business segments

                                *Exhibit 80:  Novartis AG - Key offerings

                                *Exhibit 81:  Novartis AG - Segment focus

                **10.12 Pfizer Inc.          

                                *Exhibit 82:  Pfizer Inc. - Overview

                                *Exhibit 83:  Pfizer Inc. - Business segments

                                *Exhibit 84:  Pfizer Inc. - Key offerings

                                *Exhibit 85:  Pfizer Inc. - Segment focus

***11. Appendix                            

                **11.1 Scope of the report         

                                *11.1.1 ????Market definition

                                *11.1.2 ????Objectives

                                *11.1.3 ????Notes and caveats

                **11.2 Currency conversion rates for US$            

                                *Exhibit 86: ?Currency conversion rates for US$?

                **11.3 Research Methodology 

                                *Exhibit 87: ?Research Methodology

                                *Exhibit 88: ??Validation techniques employed for market sizing?

                                *Exhibit 89: ??Information sources

                **11.4 List of abbreviations        

                                *Exhibit 90: List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases

DATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts

REPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape

PURCHASE FULL REPORT OF

sickle cell disease treatment market

QUICK BUY

Key Questions Answered

  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis